MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seres Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42−0.04 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$16.49 (−87.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Seres Therapeutics, Inc. reported revenue of $1.88M for the twelve months to Jun 30, 2026. Free cash flow was -$51.30M.
Revenue
$1.88M
TTM Q2 2026
Operating income
-$84.03M
TTM Q2 2026
Free cash flow
-$51.30M
TTM Q2 2026
EPS, diluted
-$2.33
-120.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.59M
- P/E ratio
- –
- Price to sales
- 12.53
- Price to book
- 0.68
- Dividend yield
- –
- Free cash flow yield
- -217.46%
Fundamentals
- Revenue
- $1.88M
- Net income
- -$22.46M
- EPS, diluted
- -$2.33
- Free cash flow
- -$51.30M
- Book value per share
- $3.54
- Diluted shares
- 10M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$1.88M
Operating income
-$84.03M
Net income
-$22.46M-126.1% YoY
EPS, diluted
-$2.33-120.7% YoY
Free cash flow
-$51.30M
Reported periodTrailing twelve months